Role description

Post title Professor of Haemato-oncology and Head of section of Haematological Medicine in the School of Cancer & Pharmaceutical Studies & Honorary Consultant Haematologist
Department Comprehensive Cancer Centre
School School of Cancer & Pharmaceutical Sciences
Faculty Faculty of Life Sciences & Medicine
Grade/salary NHS clinical consultant scale
Hours of work Full time (35 hours per week)
Period of appointment Indefinite contract
Reports to Professor Tony Ng, Joint Head of School, School of Cancer & Pharmaceutical Sciences
and Joint Clinical Directors, King’s College Hospital and Guy’s & St Thomas’s Hospitals
Campus Academic: Rayne Institute, King’s College London Denmark Hill Campus
Clinical: King’s College Hospital and Guy’s & St Thomas’ Hospitals

Role purpose

Research student working in lab

We would like to appoint a Professor in Haemato-oncology with an academic interest in haemato-oncology, stem cell transplantation and advanced therapies. This can involve either novel drug combination/discovery, or the development of cellular therapies, also known as Advanced Therapy Investigational Medicinal Product (ATIMP).

This new post will be based predominantly on the Denmark Hill Campus and will be strategically important for several major initiatives within the Comprehensive Cancer Centre (CCC) including the City of London Major Centre Phase II (2022-7, renewed successful), and CRUK-funded RadNet City of London (CoL) Radiation Research Unit (RRU, 2019-2024) etc. The post will collaborate with other strategic appointments to be made within the CCC e.g. Gene Editing Chair and with clinicians across campuses, within KHP Haematology.

This post will provide a strategic leadership role integrating various haematological programmes within the School of Cancer & Pharmaceutical Sciences. The current research is delivered by a number of research groups studying Sickle cell disease, Leukaemia & Myeloma, Lymphoma, Bone Marrow Failure & Myelodysplastic Syndromes, Allogeneic Stem cell Transplantation, Molecular Haematology, Myeloid Leukaemia Genomics and Biology.

This postholder will have a shared leadership role within the KHP Haematology clinical leadership model (a triad leadership model comprised of the postholder in partnership with clinicians (Clinical Directors) from King’s College Hospital and Guys and St Thomas’ Hospital).

We encourage applicants who have an internationally recognised clinical/translational research profile. The research interests of this post can range broadly, from developing advanced therapies through to patient stratification by characterising multiple components of the tumour immune microenvironment (TME). Approaches to redirect the immune microenvironment could for instance include CAR redirected T cells, BiTEs and immune checkpoint inhibitors.

Cancer cell cytotoxic T-cells

The postholder will be expected to be a Senior Clinical academic who will have a keen interest and experience of working to develop potential future therapies. Clinical stem cell transplantation and ATMP therapy within haematology is based at Denmark Hill on the King’s College Hospital site. The cell therapy programme is fully JACIE/HTA accredited for the clinical delivery of transplantation and immune effector cell therapy. It is one of the largest transplant services within Europe and in 2019 was the first centre to deliver the newly licenced CAR T-cell therapies to patients within the NHS. The service currently routinely delivers 200 transplant and 50 CAR T-cell procedures per year. Additional ATMP procedures are delivered for patients on clinical trials across a range of haematological and non-haematological disorders. The clinical facilities are fully backed up by collection and processing facilities available for the delivery of early and late phase clinical trials.

A collaborative approach in understanding immunotherapeutics at multiple levels through use of the cancer centre’s cutting-edge OMICS and imaging technologies, etc. would be advantageous for accelerating research and showcasing King’s and the Cancer Centre as an attractive partner of choice for industry.